AnalysisNews

CMMB today

$1.19+$0.05 (+4.39%)close Nov 20, 2026

Trend

DailyDowntrend (confirmed)

4 hourAscending Triangle

1 hourExpanding

15 minLeaning Bullish

5 minStrong Bearish

Daily trend turns up above $2.99

Key levels

Resistance$1.42

Resistance$1.21

Support$0.92

Latest news & SEC filings

DealSEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine

DealChemomab says SEC clears Scipher Medicine merger registration, vote set for December 4

All CMMB news →

About Chemomab Therapeutics

Chemomab Therapeutics develops antibody-based medicines for conditions involving tissue scarring and persistent inflammation. Its main candidate, nebokitug, targets the protein CCL24 and is being tested mainly in primary sclerosing cholangitis and systemic sclerosis, two rare diseases. The company is based in Israel and also has a presence in the United States.

Based on the company's 20-F filed Mar 23, 2026.

Nasdaq · Healthcare

Chemomab Therapeutics Ltd. (CMMB)

$1.19+0.05 (+4.39%)
WATCHLISTGrade: C+Risk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
1.131.261.381.511.19Oct 20Oct 28Nov 5Nov 13
High1.33
Low1.13
Open1.14
Volume70K
Avg Vol51K
VWAP1.22
30d High1.64
30d Low1.00
30d Chg-14.39%

What Is the Price Target for CMMB?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $1.15Upside: +0.0%Confidence: 20%Method: No Coverage

Is CMMB a Buy or Sell Right Now?

46
Investability Score
WATCHLIST12-18 months

Thesis

  • •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.

Test your own strategy on CMMB

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on CMMB with SEPT’s own market data.

Start Free Trial →

Is CMMB Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

N/A

Fair Value

$N/A

12

Moat Score

NONE

3/9

Piotroski Score

284.0

Altman Z-Score

What Is Smart Money Doing with CMMB?

Insider Signal

NEUTRAL

2 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Recent Insider Activity

NameTitleTypeSharesValueDate
Mor George Adidirector officerSale4,878$10KMay 29, 2026
Mor George Adidirector officerSale4,926$10KMay 29, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

CMMB Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

-53.85%

FCF Growth YoY

27.6%

Revenue Trend

UNKNOWN

Dark Pool Trades for CMMB

PREVIEW

Recent off-exchange (dark pool) prints for CMMB: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
20:58:07$1.221,838$$2KBUY
20:56:09$1.211,000$$1KSELL
20:44:48$1.201,001$$1KMIDPOINT
20:21:57$1.201,000$$1KSELL
18:30:07$1.252,211$$3KBUY

5 dark pool trades shown · $$9K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Chemomab Therapeutics Ltd. (CMMB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →

CMMB — frequently asked questions

What is CMMB stock price today?

Chemomab Therapeutics Ltd. (CMMB) is at $1.19, up 4.39% (+$0.05) at the Nov 20, 2026 close.

Why is CMMB stock moving today?

Latest CMMB news — Nov 3, 2026: SEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine · Nov 2, 2026: Chemomab says SEC clears Scipher Medicine merger registration, vote set for December 4

Did CMMB beat earnings?

CMMB last reported on Aug 19, 2026: EPS -$0.27 vs -$0.15 expected — a miss of 80.0%.

What are CMMB support and resistance levels?

Support: $0.92. Resistance: $1.21, $1.42, $1.72.

What are insiders doing with CMMB?

Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.

What is the latest news on CMMB?

Nov 3, 2026: SEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine · Nov 2, 2026: Chemomab says SEC clears Scipher Medicine merger registration, vote set for December 4